CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 5,927	$ 13
Prepaid expenses and other current assets	1,485	1,577
Total current assets	7,412	1,590
Property and equipment, net	181	235
Operating lease right-of-use asset	1,112	1,288
Other assets	29	29
Total assets	8,734	3,142
Current liabilities:
Accounts payable	2,525	5,910
Accrued clinical trials expenses	1,524	3,571
Accrued compensation	1,547	1,068
Other accrued expenses	2,632	3,600
Total current liabilities	8,228	14,149
Convertible notes at fair value, including related party amount of $17,051 and $11,689, at September 30, 2025 and December 31, 2024, respectively	17,051	11,689
Operating lease liability	957	1,145
Warrant liability	2,338	1,187
Contingent consideration liability	32	3,541
Total liabilities	28,606	31,711
Commitments and contingencies (Note 6)
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, and 11,643,786 and 555,511 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	9	4
Additional paid-in capital	413,801	403,024
Accumulated deficit	(433,682)	(431,597)
Total stockholders' deficit	(19,872)	(28,569)
Total liabilities and stockholders' deficit	$ 8,734	$ 3,142